Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Canvest (1381 HK): Trading Wide To Grandblue's Offer

Canvest (1381 HK): Evaluating A Privatisation

Quiddity Advisors

Event-Driven

Canvest Environmental Protection Group / Event-Driven

Canvest Environmental Protection Group (1381 HK)

<ul>
<li>Back on the 22 July, waste-to-energy play <a href="https://www.smartkarma.com/entities/canvest-environmental-protection-group-co-ltd" target="_blank" data-smartkarma-citation="entities:100:1" rel="noopener">Canvest Environmental (1381 HK)</a> announced a pre-conditional Offer from <a href="https://www.smartkarma.com/entities/grandblue-environment-co-a" target="_blank" data-smartkarma-citation="entities:17887:1" rel="noopener">Grandblue Environment (600323 CH)</a> at $4.90/share (best &amp; final), by way of a Scheme.</li>
<li>PRC anti-monopoly law and SAMR approvals were secured ~2.5 months from the Offer announcement. MoC, NDRC, SAMR and SAFE approvals remain outstanding. The pre-con long-stop is the 17th July 2025.</li>
<li>The transaction appears on track. However, Canvest's gross spread has widened 6.4% - out to 13.4% as I type - since <a href="https://www.smartkarma.com/entities/china-traditional-chinese-medicine" target="_blank" data-smartkarma-citation="entities:351:1" rel="noopener">China Traditional Chinese Medicine (570 HK)</a> blew up. That's excessive.</li>
</ul>


Back on the 22 July, waste-to-energy play Canvest Environmental (1381 HK) announced a pre-conditional Offer from Grandblue Environment (600323 CH) at $4.90/share (best &amp; final), by way of a Scheme.
PRC anti-monopoly law and SAMR approvals were secured ~2.5 months from the Offer announcement. MoC, NDRC, SAMR and SAFE approvals remain outstanding. The pre-con long-stop is the 17th July 2025.
The transaction appears on track. However, Canvest's gross spread has widened 6.4% - out to 13.4% as I type - since China Traditional Chinese Medicine (570 HK) blew up. That's excessive.


China Traditional Chinese Medicine (570 HK)

Canvest (1381 HK): This Is Trading Too Wide